Company intelligence / Profile preview

SciRhom GmbH

Martinsried/Planegg, Bavaria, Germanyscirhom.com ↗

Ownership: Private
Development stage: Phase 1

Overview

SciRhom has received CTA approval and plans to initiate its first clinical study in Austria in the second half of 2024. The study will evaluate safety in healthy volunteers and provide initial evidence of clinical activity. Preclinical data has shown promise in rheumatoid arthritis and inflammatory bowel disease models[1][5][6].

Therapeutic areas: Immunology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

SR-878

Partnerships

Hospital for Special Surgery (HSS)

Beyond the preview

Go deeper on SciRhom GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciRhom GmbH.